Micromed, Inc.

Micromed, Inc. specializes in electrophysiological and neurological monitoring devices. Their portfolio includes standalone electroencephalographs (EEG) and EEG modules for patient monitoring systems, ophthalmic flash generators for retinal imaging, polysomnographs for sleep disorder diagnostics, bioelectrical signal analysis software, and somatosensory electrical stimulation systems for therapeutic use. These devices are designed to capture, analyze, and interpret electrical activity in the brain and nervous system, as well as support diagnostic and treatment applications.

Micromed, Inc. is headquartered in the United States. Since the FDA regulates medical devices in the US, the company’s devices must comply with FDA requirements, including classification, premarket submission pathways (such as 510(k) clearances or De Novo authorizations), and post-market reporting. The US location means their devices are subject to FDA oversight, ensuring they meet safety and performance standards before entering the market.

Micromed, Inc.’s devices are listed in the FDA’s 510(k) Premarket Notification Database and the Unique Device Identifier (UDI) Registry. These registries are maintained to track devices that have undergone FDA review and received clearance via pathways like 510(k) submissions or De Novo authorizations. Listing in these databases confirms that the devices meet regulatory requirements for market authorization in the US, ensuring transparency for healthcare providers and regulators.

All of Micromed, Inc.’s devices fall under FDA Class II classification, which means they pose moderate risk and require special controls beyond general controls to ensure safety and effectiveness. Class II devices typically require premarket notification (510(k)) or De Novo review to demonstrate substantial equivalence to a legally marketed predicate device or to establish safety and performance through alternative pathways. This classification ensures rigorous evaluation before authorization.

Micromed, Inc.’s devices are authorised via the FDA’s 510(k) clearance process or the De Novo pathway. The 510(k) pathway demonstrates that a device is substantially equivalent to a legally marketed predicate device in terms of technology, performance, and intended use. The De Novo pathway is used for novel devices without a predicate, where the FDA reviews safety and effectiveness data to establish regulatory requirements. Both pathways ensure devices meet FDA standards before commercialization.